Tuas Biomedical Park Tenants
CIBA Vision started manufacturing contact lenses at its Singapore facility in March. The 210,000 square foot plant employs 220 people, and will grow to 500 workers. When at full capacity, "it will be our largest manufacturing site in terms of size," says Mike Dilworth, vp, global supply chain for CIBA Vision, based in Atlanta, GA.
The Singapore site manufactures Focus Dailies, a type of contact lens that is replaced daily and need no cleaning. "They're an ideal option for people with allergies, because one-day use reduces the chance of the build-up of pollen and other debris," says Dilworth.
CIBA Vision manufactured more than one billion Focus Dailies in 2004, and the Singapore plant will produce an additional 800 million lenses a year. The company has invested $85 million in the Singapore plant, and plans to invest a total of $250 million over the next few years.
The Singapore facility will include a distribution center and warehouse for a range of lenses that will be distributed globally. "Singapore provides a strategic location for manufacturing and distribution, including good infrastructure, an international airport hub, and technical work force," says Dilworth.
In April, MDS Pharma Services (www.mdsps.com), a provider of innovative drug discovery and development services, hosted the grand opening of its expanded laboratory facility in Singapore. The expanded facility provides central lab testing and global development of clinical trials.
"We run clinical trials for pharmaceutical and biotechnology companies worldwide," says Scott Neilson, general manager of global center labs for MDS Pharma Services.
The Singapore location can tap into Asian populations for clinical testing. Singapore's diverse patient population, motivated and experienced investigators, and the government's support for pharmaceutical companies attracted MDS Pharma Services, a part of MDS, headquartered in Toronto, Canada.
MDS Sciex, the scientific instruments division of MDS, will open a new plant in September to manufacture its Cellular Analysis MiWave product line, used for secondary screening in drug discovery.
Later, a line of mass spectrometers will be made there. The plant will employ 50 people when it opens and peak at 100 workers. "We want a significant footprint in one of the fastest growing markets for scientific instruments," says Andy Boorn, Ph.D., president of MDS Sciex.
A full range of fee-for-service chemistry technologies, including medicinal chemistry and custom organic sythesis, are performed by experts at the Albany Molecular Research Singapore, a wholly owned subsidiary of Albany Molecular Research (www.amri. com) in Albany, NY.
"The large concentration of pharmaceutical companies made Singapore a logical place for a new location," says Michael Trova, Ph.D., vice president of chemistry. The Singapore facility will help the company to provide chemistry services at competitive prices to international clients. The staff of 10 in Singapore is expected to grow to 40 workers.